SOURCE: Benda Pharmaceutical, Inc.

October 04, 2007 12:29 ET

Going Global: Gendicine Results to Be Presented at Leading European Symposium

HUBEI PROVINCE, CHINA--(Marketwire - October 4, 2007) - Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer, announced today that Gendicine® will receive its formal international introduction at the 15th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Rotterdam, The Netherlands from October 27 to October 30, 2007. Five leading Chinese scientists and physicians including Dr. Zhaohui Peng, SiBiono chairman and the creator of Gendicine®, will present the Gendicine® post-clinical trials results that were recently met with such overwhelming enthusiasm in China. (Click here to view that story; the full link is included at the base of this release.)

As a featured topic at the 15th Annual ESGCT Congress, Gendicine® is entering onto the global stage. The 700 member ESGCT is one of the world's leading and most influential professional bodies in promoting basic and clinical research in gene therapy, cell therapy, and genetic vaccines. The ESGCT serves as professional adviser to the general gene therapy community and to European regulatory bodies.

"The presentation of post-clinical trials results at the ESGCT Congress marks a watershed moment for Gendicine® and for the global fight against cancer," stated Yiqing Wan, Benda CEO. "The international medical community will learn what thousands of cancer patients already know -- a revolutionary, potentially highly effective cancer treatment is available -- today -- in China in the form of Gendicine®."

Encouraged by the demonstrated effectiveness of Gendicine®, approximately 1,800 foreign patients have already traveled to China for Gendicine® treatment. As molecular biologist Masatoshi Tagawa, of Japan's Chiba University, commented during a recent "Chemistry World" interview, "The results will encourage cancer patients and they are asking for any kind of possibility to survive."

In 2006, there were 3.2 million new cancer cases diagnosed in European Union, and total cancer drug expenditures grew to EUR 50.5 billion. (Source: European Parliament Study).

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (, a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.

Benda Investor Resources

News Release -- "Record $3.8 M in Gendicine® Orders in One Day Sells Out All Available Product; Promising Reported Results Drive Unprecedented Demand":

Fact Sheet:

PowerPoint Presentation:

Gendicine Video:


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information